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Abstract: Siphonaxanthin is a specific keto-carotenoid in green algae whose bio-functional 
properties are yet to be identified. This review focuses on siphonaxanthin as a bioactive 
compound and outlines the evidence associated with functionality. Siphonaxanthin has 
been reported to potently inhibit the viability of human leukemia HL-60 cells via induction 
of apoptosis. In comparison with fucoxanthin, siphonaxanthin markedly reduced cell 
viability as early as 6 h after treatment. The cellular uptake of siphonaxanthin was 2-fold 
higher than fucoxanthin. It has been proposed that siphonaxanthin possesses significant 
anti-angiogenic activity in studies using human umbilical vein endothelial cells and rat 
aortic ring. The results of these studies suggested that the anti-angiogenic effect of 
siphonaxanthin is due to the down-regulation of signal transduction by fibroblast growth 
factor receptor-1 in vascular endothelial cells. Siphonaxanthin also exhibited inhibitory 
effects on antigen-induced degranulation of mast cells. These findings open up new 
avenues for future research on siphonaxanthin as a bioactive compound, and additional 
investigation, especially in vivo studies, are required to validate these findings. In addition, 
further studies are needed to determine its bioavailability and metabolic fate.  
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1. Introduction 
Marine algae are a potential renewable resource in the marine environment that are used as a 
culinary item in East Asia and they have been reported to confer several beneficial effects in human 
health. They are an excellent source of nutritional and bioactive compounds, such as carotenoids, 
dietary fibers, amino acids, essential fatty acids, vitamins, and minerals [1,2]. Algal carotenoids have 
received much attention, as they are structurally different from those found in terrestrial plants. It is 
important to characterize the novel bio-functional activities of carotenoids from marine algae.  
One of the major carotenoids in marine algae is fucoxanthin, and it is found mainly in brown 
macroalgae and in some classes of microalgae [3–5]. The chemical structure of fucoxanthin includes 
an allenic bond and oxygenic functional groups, such as hydroxyl, epoxy, carbonyl, and acetyl groups, 
in addition to its polyene chain (Figure 1A). Recently, fucoxanthin has been reported to possess several 
beneficial effects related to its anti-cancerous, anti-oxidative, and anti-obesity properties [6–12]. 
Moreover, fucoxanthin induces uncoupling protein 1 in the mitochondria of abdominal white adipose 
tissue, leading to the oxidation of fatty acids and heat production [13]. On the other hand, we found 
that fucoxanthin and its deacetylated product, fucoxanthinol, effectively suppress angiogenesis [14]. 
This implies that fucoxanthin, with its anti-angiogenic activity, would be useful in preventing 
angiogenesis-related diseases such as cancer and diabetic retinopathy. Consequently, brown algal 
fucoxanthin seems to be a useful bioactive and nutraceutical compound for human health. 
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Scientific evidence on the bio-functional properties of algal carotenoids is still very limited. 
Siphonaxanthin (Figure 1B) is a specific keto-carotenoid of green algae, and its bio-functional 
properties are yet to be clarified. We focus on the potential of siphonaxanthin as a bioactive compound 
and outline the evidence associated with functionality functionality. The objective of this review is to 
summarize the novel bio-functional activities of green algal siphonaxanthin that have been highlighted 
in our studies. 
2. Siphonaxanthin in Green Algae 
Siphonaxanthin is a specific keto-carotenoid of siphonaceous green algae, which helps in absorbing 
available green and blue green light under water [15,16]. Brown algal fucoxanthin has epoxide and an 
allenic bond in its structure, whereas siphonaxanthin does not contain either of those functional groups. 
However, it possesses an additional hydroxyl group on the 19th carbon atom (Figure 1B). In edible 
green algae such as Codium fragile, Caulerpa lentillifera, and Umbraulva japonica, siphonaxanthin 
content is approximately 0.03%–0.1% of the dry weight. Siphonein, identified as siphonaxanthin  
19-(trans-∆2-dodecenoate), is present at the same level as siphonaxanthin in these algae. C. fragile is 
consumed as a part of the staple diet in ancient Japanese food culture.  
Generally, carotenoids in plants play important roles in the photosynthetic process, such as  
light-absorption and quenching of excess energy [17]. β-Carotene is present in most of the divisions of 
the reaction-center complexes (RC) and the light-harvesting complexes (LHC) of photosystem I (PSI). 
On the other hand, in the peripheral LHC of photosystem II (PSII), the bound carotenoids are 
heterogenous, depending on the classes [5]. In green algae, the major carotenoid in the peripheral LHC 
of PSII is siphonaxanthin, which exhibited an additional absorption band (the 535 nm band) in the blue 
to green region. β-Carotene in both RC and LHC-PSI might have protective functions, and carotenoids 
in the peripheral LHC of PSII might have primarily light-harvesting functions. Employing 
femtosecond time-resolved fluorescence spectroscopy to analyze purified carotenoids in organic 
solvents and the LHC in solution, this keto-carotenoid was found to facilitate highly efficient energy 
transfer of carotenoids to chlorophylls [18]. Siphonaxanthin might have a largely light-harvesting 
function in the green light-rich underwater habitat [19]. 
3. Apoptosis-Inducing Effect 
There is a wealth of information pertaining to apoptosis in anti-cancer research, and the  
apoptosis-inducing properties of carotenoids may be an important approach to chemo-prevention 
and/or chemotherapy. Carotenoids from terrestrial plants, such as β-carotene and lycopene, have been 
extensively studied and implicated as cancer preventive agents. Carotenoids from marine sources have 
received much attention, as they are structurally different from those found in terrestrial sources. 
Recent studies have found that carotenoids from algae, including fucoxanthin and peridinin, induce 
apoptosis in cancer cells [6–9,20,21].  
We investigated whether various carotenoids present in marine sources are potentially involved in 
cancer-preventing action in human leukemia HL-60 cells. We found that the 11 carotenoids 
investigated, siphonaxanthin most potently at inhibiting the viability of HL-60 cells [22]. Compared to 
fucoxanthin, siphonaxanthin, at a concentration of 20 μM, markedly reduced cell viability as early as 6 h 
Mar. Drugs 2014, 12 3663 
 
after treatment. The cellular uptake of siphonaxanthin was 2-fold higher than fucoxanthin, 
demonstrating a positive correlation between cellular uptake and cell viability. The apoptotic activity 
of siphonaxanthin was characterized by increases in TUNEL-positive cells, and by increased 
chromatin condensation in the cells. This induction of apoptosis was accompanied by decreased 
expression of Bcl-2, and subsequent increase in the activation of caspase-3. These observations 
indicate that siphonaxanthin may be a more potent growth-inhibitor in cancer cells than fucoxanthin, 
possibly due to the differences in the structure of their different functional groups. The presence of 
hydroxyl group on the 19th carbon atom appeared to contribute to the strong apoptosis-inducing effect. 
This is further supported by the fact that siphonein (Figure 1C), an esterified form of siphonaxanthin 
that does not contain an additional hydroxyl group, had a reduced inhibitory effect on cell viability.  
Interestingly, siphonaxanthin has been reported to up-regulate the expression of death receptor 5 
(DR5) [22]. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes apoptosis 
selectively in tumor cells without much effect on normal cells by binding to the transmembrane 
receptors TRAIL-R1/DR4 and TRAIL-R2/DR5 [23]. Thus, any chemotherapeutic agent that activates 
TRAIL-induced apoptosis in cancer cells may be an attractive strategy in anti-cancer research.  
Yoshida et al. reported that halocynthiaxanthin and peridinin sensitize cancer cells to TRAIL-induced 
apoptosis by up-regulating the expression of DR5 [21], which indicates that some carotenoids can 
induce apoptosis through this pathway. In our study, siphonaxanthin potently up-regulated the 
expression of DR5, but fucoxanthin did not [22]. Siphonaxanthin could be potentially useful as a 
chemopreventive and/or chemotherapeutic agent. 
4. Anti-Angiogenic Effect 
Angiogenesis is characterized by the growth and remodeling process of the primitive network of 
blood vessels into a complex network. In this process, endothelial cells secrete proteases, migrate 
through the extracellular matrix, proliferate, and differentiate [24]. Angiogenesis is involved in many 
physiological and pathological situations. In normal adults, most vasculature is quiescent, with only 0.01% 
of endothelial cells undergoing division [25]. However, angiogenesis is an essential process in the 
female reproductive cycle, along with the remodeling and regeneration of tissues [26]. Pathological 
angiogenesis is implicated in the pathogenesis of many diseases, including cancer, atherosclerosis, 
diabetic retinopathy, and rheumatoid arthritis [27]. The newly-formed blood vessels promote cancer 
growth by supplying nutrients and oxygen and by removing waste products. Metastasis also depends 
on angiogenesis, as tumor cells are shed from a primary tumor and grow in their target organs [28]. 
Angiogenesis is activated under other pathological conditions, such as ocular and inflammatory 
disorders [29]. Hence, prevention of angiogenesis under pathological conditions is a promising 
approach in the prevention of cancer and other pro-angiogenic diseases. It has been reported that some 
natural products, such as vitamin B6 [30], algal polysaccharides [31], and nasunin [32], suppress 
angiogenesis. Given this background, studies on natural bioactive molecules from marine algae have 
reported that fucoidans, polysaccharides from marine brown algae, and fucoxanthin and its deacetylated 
product, fucoxanthinol, exert anti-angiogenic properties [14,33]. 
To evaluate the anti-angiogenic effect of siphonaxanthin from green algae, we examined its  
anti-angiogenic effect in cell culture model systems and by employing ex vivo approaches using human 
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umbilical vein endothelial cells (HUVECs) and rat aortic ring [34,35], respectively. Siphonaxanthin 
significantly suppressed HUVEC proliferation at relatively lower concentration of 2.5 µM, while its 
effect on chemotaxis was not significant [36]. In addition, siphonaxanthin exhibited a strong inhibitory 
effect on HUVEC tube formation in an in vitro angiogenesis model. Siphonaxanthin suppressed the 
tube length at a concentration of 10 µM, while no tube formation was observed at 25 µM, suggesting 
that this could be due to the suppression of angiogenic mediators. The ex vivo angiogenesis assay using 
rat aortic ring indicated reduced microvessel outgrowth in a dose-dependent manner, and the reduction 
was significant at concentrations of more than 2.5 µM.  
To elucidate the molecular mechanism underlying the anti-angiogenic activity of siphonaxanthin 
compared to fucoxanthin, we focused on the vascular specific pro-angiogenic factor, vascular 
endothelial growth factor (VEGF), and the other angiogenic factors, such as fibroblast growth factors 
(FGFs) [37,38]. It has been shown that both siphonaxanthin and fucoxanthin suppress the mRNA 
expression of fibroblast growth factor 2 (FGF-2) and its receptor (FGFR-1), as well as their trans-activation 
factor, EGR-1 [39]. These suppressive effects of siphonaxanthin were more effective than fucoxanthin. 
However, the mRNA expression of VEGFR-2, a potent signal transducer involved in the  
VEGF-mediated signaling pathway, was not significantly affected by these carotenoids. Furthermore, 
these two marine algal carotenoids can down-regulate the phosphorylation of FGF-2-mediated 
intracellular signaling proteins such as ERK1/2 and Akt. Inhibition of FGF-2-mediated intracellular 
signaling proteins by these carotenoids represses the migration of endothelial cells, as well as their 
differentiation into tube-like structures on Matrigel. These results demonstrate, for the first time, the 
possible molecular mechanism underlying the anti-angiogenic effect of these two algal carotenoids and 
suggest that their anti-angiogenic effect is due to the down-regulation of signal transduction by  
FGFR-1 in vascular endothelial cells. Siphonaxanthin exhibited its anti-angiogenic effect at lower 
concentrations than fucoxanthin, indicating its potential as a strong angiogenesis inhibitor.  
These findings provide new insights into the novel bio-functional property of marine algal carotenoids, 
especially that of siphonaxanthin, which has the potential to enhance current anti-angiogenic therapies 
in the treatment of cancer and other pro-angiogenic diseases. 
5. Anti-Inflammatory Effect 
Currently, one of the most common social problems in the world is an increasing number of patients 
with type I allergy. Mast cells play pivotal roles in localized inflammation and immediate type allergic 
reactions by secreting biologically active substances including histamine, eicosanoids, proteolytic 
enzymes, cytokines, and chemokines after antigen-induced degranulation. The antigen-induced 
aggregation of the high affinity IgE receptor (FcεRI) expressed on the cell surface triggers the 
degranulation of mast cells [40]. We have previously reported that astaxanthin, β-carotene, 
fucoxanthin, and zeaxanthin significantly inhibit antigen-induced degranulation of rat basophilic leukemia 
RBL-2H3 cells, which were used as a mast cell model, and bone marrow-derived mast cells [41]. 
Interestingly, these carotenoids inhibited antigen-induced translocation of FcεRI to lipid rafts, which 
are known as platforms of the aggregation of FcεRI [42]. Furthermore, oral administration of these 
four carotenoids for a week significantly inhibited dinitrofluorobenzene (DNFB)-induced ear swelling 
and the increased content of histamine in the DNFB-treated mice [43]. These results suggested that 
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dietary carotenoids exert an anti-inflammatory effect by suppressing mast cell degranulation in vivo. 
However, information about the anti-degranulation effect of the other carotenoids is limited. 
In this context, we evaluated the effects of eleven additional carotenoids using the RBL-2H3 cells. 
Results from our screening showed that nine carotenoids, including siphonaxanthin, had inhibitory 
effects on antigen-induced degranulation of mast cells [44]. The inhibitory activity of carotenoids was 
not related to their cellular uptake. It is speculated that carotenoids, including siphonaxanthin, may 
modify the functions of lipid rafts by localizing in the cell membrane and inhibiting the translocation 
of FcεRI to lipid rafts. Nevertheless, it is important to verify whether carotenoids affect other signaling 
pathways involved in lipid rafts in order to understand the biological relationship between carotenoids 
and lipid rafts. 
6. Conclusions and Future Perspectives 
To clarify the biological action of siphonaxanthin, further studies are required to determine its 
bioavailability and biological metabolism. Our previous studies, using cultured cells and mice, 
demonstrated that orally administered fucoxanthin is metabolized to fucoxanthinol and 
amarouciaxanthin A in the intestinal tract and liver, respectively [45,46]. However, information on the 
bioavailability and metabolic conversion of siphonaxanthin in vivo are limited. Siphonein, which is 
identified as siphonaxanthin 19-(trans-∆2-dodecenoate) is present in similar levels as that of 
siphonaxanthin in siphonaceous green algae. Based on our data using cultured cells and ex vivo studies, 
the biological functions of siphonein were found to be weaker than those of siphonaxanthin.  
If siphonein could be hydrolyzed in the intestine by digestive enzymes and absorbed in a manner 
similar to siphonaxanthin, oral administration of siphonein could be expected to exert the same 
biological activities as siphonaxanthin.  
Siphonaxanthin isolated from marine green algae, such as C. fragile, remarkably suppresses cell 
viability, induces apoptosis in cancer cells, and possesses more potent anti-angiogenic activity than 
fucoxnathin. Although several reports have indicated that fucoxanthin could be immensely beneficial 
to human health, our studies indicate that siphonaxanthin is more effective than fucoxanthin. Nevertheless, 
these findings uncover new avenues for future research on siphonaxanthin as a bioactive compound, 
and additional investigation, especially in vivo studies, are needed to validate the reported findings.  
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